Ph.D., University of Michigan, Human Genetics, 1976.
M.D., American University of Beirut, 1972.
Dr. Hanash's interests and expertise focus on the development and application of integrated approaches to the molecular profiling of cancer, with particular emphasis on proteomics. Dr. Hanash's Ph.D. training is in Human Genetics and clinical training in Pediatric Oncology. He has been a program principal investigator (PI) for multi-investigator projects funded by the National Cancer Institute (NCI) while at the University of Michigan, including program projects and most recently, PI for an NCI-funded Director's Challenge program, which focuses on molecular profiling of lung, colon and ovarian cancer and PI of an NCI-funded Cancer Biomarker Development program, which focuses on the application of proteomics to the discovery of protein markers for the early diagnosis of lung and GI cancers. Dr. Hanash has organized and participated in several workshops sponsored by the NCI related to cancer diagnostics and molecular profiling. Dr. Hanash relocated from the University of Michigan to the Fred Hutchinson Cancer Research Center in August 2004 to lead a newly developed program in Molecular Diagnostics.
Human Proteome Organisation - Founding Member
American Association for Cancer Research
American Society for Cell Biology
American Society for Human Genetics
American Society for Pediatric Research
American Society of Hematology
Children's Cancer Study Group
Human Proteome Organisation
1992-1999, Director, University of Michigan, Cancer Center, Carcinogenesis
1989-2004, Professor, University of Michigan, Pediatrics
1984-1989, Associate Professor, University of Michigan, Pediatrics
1979-1984, Assistant Professor, University of Michigan, Pediatrics
1978-1979, Instructor, University of Michigan, Pediatrics
1978-1979, Fellow, University of Michigan, Pediatric Hematology
1973-1976, Post-doctoral Fellow, University of Michigan, Medical School, Human Genetics
Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival.. Cancer research. 75(9):1789-800.. 2015.
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.. Journal of the National Cancer Institute. 107(8). 2015.
Enrichment strategies in glycomics based lung cancer biomarker development.. Proteomics. Clinical applications.. 2013.
Imaging a functional tumorigenic biomarker in the transformed epithelium.. Proceedings of the National Academy of Sciences of the United States of America. 110(1):93-8.. 2013.
Fibulin-2 is a driver of malignant progression in lung adenocarcinoma.. PloS one. 8(6):e67054.. 2013.
A Novel Soluble Form of Tim-3 Associated with Severe Graft-versus-Host Disease.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(9):1323-30.. 2013.
Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.. Breast cancer research and treatment. 135(2):611-8.. 2012.
Unleashing the Power of Proteomics to Develop Blood-Based Cancer Markers.. Clinical chemistry.. 2012.
Microparticles From Ovarian Carcinomas Are Shed Into Ascites and Promote Cell Migration.. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 22(4):546-552.. 2012.
Evaluation of Known Oncoantibodies, HER2, p53, and Cyclin B1, in Prediagnostic Breast Cancer Sera.. Cancer prevention research (Philadelphia, Pa.).. 2012.
Increased plasma levels of the APC-interacting protein MAPRE1, LRG1 and IGFBP2 preceding a diagnosis of colorectal cancer in women.. Cancer prevention research (Philadelphia, Pa.). 5(4):655-664.. 2012.
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.. Cancer cell. 20(3):289-99.. 2011.
Emerging molecular biomarkers--blood-based strategies to detect and monitor cancer.. Nature reviews. Clinical oncology. 8(3):142-50.. 2011.
Integrated mass spectrometry-based analysis of plasma glycoproteins and their glycan modifications.. Nature protocols. 6(3):253-69.. 2011.
Progress in mining the human proteome for disease applications.. Omics : a journal of integrative biology. 15(3):133-9.. 2011.
A proteomics platform combining depletion, multi-lectin affinity chromatography (M-LAC), and isoelectric focusing to study the breast cancer proteome.. Analytical chemistry. 83(12):4845-54.. 2011.
Mining the plasma proteome for disease applications across seven logs of protein abundance.. Journal of proteome research. 10(1):46-50.. 2011.
Confounding effects of hormone replacement therapy in protein biomarker studies.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 20(1):134-9.. 2011.
Targets of the Tumor Suppressor miR-200 in Regulation of the Epithelial-Mesenchymal Transition in Cancer.. Cancer research. 71(24):7670-7682.. 2011.
Tumor Microenvironment-Derived Proteins Dominate the Plasma Proteome Response during Breast Cancer Induction and Progression.. Cancer research. 71(15):5090-100.. 2011.
Harnessing the immune response for cancer detection.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 20(4):569-70.. 2011.
Comprehensive Proteomic Profiling of Aldehyde Dehydrogenases in Lung Adenocarcinoma Cell Lines.. International journal of proteomics. 2011:145010.. 2011.